Clearside Biomedical Files 8-K on Delisting and Shareholder Vote

TL;DR

Clearside Biomedical might be delisted, and they're having a shareholder vote.

AI Summary

Clearside Biomedical, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy continued listing rules and the submission of matters to a vote of security holders. The company, incorporated in Delaware with its principal executive offices in Alpharetta, Georgia, is in the pharmaceutical preparations industry.

Why It Matters

This filing indicates potential issues with Clearside Biomedical's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — The filing explicitly mentions a notice of delisting or failure to satisfy continued listing rules, which is a significant risk for the company and its shareholders.

Key Numbers

• 001-37783 — SEC File Number (Identifies the company's filing history with the SEC.)
• 45-2437375 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Clearside Biomedical, Inc. (company) — Registrant
• August 28, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Alpharetta, Georgia (location) — Principal Executive Offices
• 2834 (sic_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
• $50,000,000 — alue of Listed Securities (" MVLS ") of $50,000,000 required for continued listing on The N
• $1.00 — he Company's common stock was less than $1.00 per share for the previous 30 consecuti

Filing Documents

• clsd-20250828.htm (8-K) — 57KB
• 0001193125-25-194994.txt ( ) — 162KB
• clsd-20250828.xsd (EX-101.SCH) — 24KB
• clsd-20250828_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 28, 2025, Clearside Biomedical, Inc. (the " Company ") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that the listing of its common stock was not in compliance with the minimum Market Value of Listed Securities (" MVLS ") of $50,000,000 required for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the " MVLS Requirement "). The notice has no present impact on the listing of the Company's securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until February 24, 2026 (the " Compliance Date "), to regain compliance with the MVLS Requirement. To regain compliance, the Company's MVLS must close at $50,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date. In the event the Company does not regain compliance with the MVLS Requirement prior to the Compliance Date, Nasdaq will notify the Company that its securities are subject to delisting, at which point the Company may appeal the delisting determination to a Nasdaq hearings panel. The Company intends to actively monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the MVLS Requirement. The Company may also pursue transferring the listing of its common stock to The Nasdaq Capital Market. As previously disclosed, on February 7, 2025, the Company received a notice from the Nasdaq notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company's common stock was less than $1.00 per share for the previous 30 consecutive business days (the " Minimum Bid Price Requireme

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On August 29, 2025, the Company held a special meeting of stockholders (the " Special Meeting "). At the Special Meeting, the Company's stockholders considered one proposal, which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on August 4, 2025 (the " Proxy Statement "). Of the 78,510,318 shares outstanding as of the record date, 49,164,237 shares, or 62.62%, were present or represented by proxy at the Special Meeting. Set forth below are the results of the matter submitted for a vote of stockholders at the Special Meeting. Proposal No. 1 : Approval of a series of alternate amendments to the Company's Restated Certificate of Incorporation to effect, at the option of the Board, a reverse stock split of its common stock at a ratio in the range of 1-for-5 to 1-for-15, inclusive (the " Reverse Stock Split "), and a corresponding proportionate reduction in the total number of authorized shares of the Company's common stock, with such ratio to be determined by the Board in its sole discretion. The votes were cast as follows: Votes For Votes Against Abstained 46,485,055 2,220,186 458,996

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR